Department of Pediatric Rheumatology, Faculty of Medicine, MD, Kocaeli University, Kocaeli, Turkey.
Department of Pediatric Rheumatology, Ankara Etlik City Hospital, Ankara, Turkey.
Eur J Pediatr. 2024 Oct;183(10):4337-4343. doi: 10.1007/s00431-024-05703-3. Epub 2024 Jul 31.
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome (PFAPA) are the most common autoinflammatory syndromes in children. This study aimed to evaluate the clinical and laboratory parameters that may predict colchicine responsiveness.This retrospective, multicenter, cross-sectional study involved nine pediatric rheumatology centers from our country., The patients diagnosed with PFAPA were compared on the basis of their responses to colchicine. In the 806 (42.3% female 57.7% male) patients, the most common clinical findings were fever (100%), exudative tonsillitis (86.5%), pharyngitis (80.9%), and aphthous stomatitis (50.5%). The mean attack frequency was 13.5 ± 6.8 attacks per year lasting for a mean of 3.9 ± 1.1 days. Colchicine treatment was attempted in 519 (64.4%) patients, with 419 (80.7%) showing a favorable response. In patients who underwent MEFV gene analysis (70.8%), the most common variant was M694V heterozygous (16.8%). The presence of pharyngitis (p = 0.03, 95% CI 0.885 to 0.994), the presence of arthralgia (p = 0.04, 95% CI 0.169 to 0.958), and having more frequent attacks (p = 0.001, 95% CI 0.028 to 0.748) were found to be associated with colchicine unresponsiveness, whereas the carriage of the M694V variant (p = 0.001, 95% CI 0.065 to 0.242) was associated with colchicine responsiveness.
This study identified the presence of pharyngitis, arthralgia, and increased attack frequency in patients with PFAPA as factors predicting colchicine unresponsiveness, whereas the carriage of the M694V variant emerged as a predictor of colchicine responsiveness. Predicting colchicine response at disease onset may facilitate a more effective management of PFAPA.
• Colchicine treatment can be used in the prophylaxis of PFAPA disease. • Having the MEFV variant is the most commonly known factor in predicting response to colchicine.
• The presence of pharyngitis or arthralgia, and more frequent attacks in PFAPA disease were found to be independently associated with colchicine unresponsiveness. • Carrying the M694V variant was identified as the sole factor predicting colchicine responsiveness.
评估可能预测秋水仙碱反应性的临床和实验室参数。
本回顾性、多中心、横断面研究纳入了来自我国 9 个儿科风湿病中心的患者。根据对秋水仙碱的反应,对诊断为 PFAPA 的患者进行比较。在 806 例(42.3%女性,57.7%男性)患者中,最常见的临床发现是发热(100%)、渗出性扁桃体炎(86.5%)、咽炎(80.9%)和口疮性口炎(50.5%)。平均发作频率为每年 13.5±6.8 次,持续时间平均为 3.9±1.1 天。519 例(64.4%)患者尝试了秋水仙碱治疗,其中 419 例(80.7%)反应良好。在接受 MEFV 基因分析的患者(70.8%)中,最常见的变异是 M694V 杂合子(16.8%)。存在咽炎(p=0.03,95%CI 0.885 至 0.994)、关节炎(p=0.04,95%CI 0.169 至 0.958)和更频繁的发作(p=0.001,95%CI 0.028 至 0.748)与秋水仙碱无反应相关,而携带 M694V 变异(p=0.001,95%CI 0.065 至 0.242)与秋水仙碱反应性相关。
本研究确定了 PFAPA 患者存在咽炎、关节炎和发作频率增加是预测秋水仙碱无反应的因素,而携带 M694V 变异是预测秋水仙碱反应性的因素。在疾病发作时预测秋水仙碱的反应可以更有效地管理 PFAPA。
秋水仙碱治疗可用于预防 PFAPA 疾病。携带 MEFV 变异是预测秋水仙碱反应的最常见因素。
PFAPA 疾病中存在咽炎或关节炎以及更频繁的发作与秋水仙碱无反应独立相关。携带 M694V 变异被确定为唯一预测秋水仙碱反应性的因素。